LBIO Lion Biotechnologies Inc

Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma

Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
EN
05/10/2020

Underlying

LBIOLion Biotechnologies Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lion Biotechnologies Inc

 PRESS RELEASE
Free
LBIO Lion Biotechnol...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 20, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 312,660 shares of Iovance’s common stock to 58 new, non-executive emp...

June 23, 2025 1 EN
 PRESS RELEASE
Free
LBIO Lion Biotechnol...

Iovance Biotherapeutics to Present at Upcoming Conference

Iovance Biotherapeutics to Present at Upcoming Conference SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conference: Goldman Sachs Global Healthcare ConferenceFireside Chat: June 11, 2025 at 1:20 p.m. ETMiami, FL The live and archived webcasts will be available at . About Iovance Biotherapeutics,...

June 10, 2025 1 EN
 PRESS RELEASE
Free
LBIO Lion Biotechnol...

The Journal of Clinical Oncology Publishes Five-year Analysis of Amtag...

The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma One-time Amtagvi Treatment Continues to Show Deep, Durable Responses and Meaningful Survival One Third of Responses Remain Ongoing without Subsequent Treatment after Five Years Simultaneous Presentation at ASCO 2025 SAN CARLOS, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for p...

June 2, 2025 1 EN
 PRESS RELEASE
Free
LBIO Lion Biotechnol...

Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patien...

Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor SAN CARLOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

May 22, 2025 1 EN
 PRESS RELEASE
Free
LBIO Lion Biotechnol...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 15, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 278,770 shares of Iovance’s common stock to 59 new, non-executive emplo...

May 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch